# What Should be the Next Vasopressor for Severe Septic Shock? Methylene Blue or Terlipressin

> **NCT03038503** · PHASE3 · UNKNOWN · sponsor: **Ramathibodi Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Septic Shock
- Refractory Shock

## Interventions

- **DRUG:** Methylene Blue
- **DRUG:** Terlipressin

## Key facts

- **NCT ID:** NCT03038503
- **Lead sponsor:** Ramathibodi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2018-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03038503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03038503, "What Should be the Next Vasopressor for Severe Septic Shock? Methylene Blue or Terlipressin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03038503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*